Glucose excursions between states of glycemia with progression to type 1 diabetes in the Diabetes Prevention Trial-Type 1 (DPT-1)

Diabetes

Volumn 59, Issue 10, 2010, Pages 2386-2389

  Sosenko, Jay M ^a   Skyler, Jay S ^a   Krischer, Jeffrey P ^b   Greenbaum, Carla J ^c   Mahon, Jeffrey ^d   Rafkin, Lisa E ^a   Cuthbertson, David ^b   Cowie, Catherine ^e   Herold, Kevan ^f   Eisenbarth, George ^g   Palmer, Jerry P ^h  

^a UNIVERSITY OF MIAMI   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c BENAROYA RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF WESTERN ONTARIO   (Canada)

^e NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^f YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF COLORADO   (United States)

^h UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; GLUCOSE;

ARTICLE; DIABETOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; HUMAN; INSULIN BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET CELL FUNCTION; PRIORITY JOURNAL;

AREA UNDER CURVE; BLOOD GLUCOSE; C-PEPTIDE; DIABETES MELLITUS, TYPE 1; DISEASE PROGRESSION; GLUCOSE TOLERANCE TEST; HUMANS; PREDIABETIC STATE; REFERENCE VALUES;

EID: 77957564957     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db10-0534     Document Type: Article

References (15)

1. Sosenko JM, Palmer JP, Rafkin-Mervis L, Krischer JP, Cuthbertson D, Mahon J, Greenbaum CJ, Cowie CC, Skyler JS, the Diabetes Prevention Trial-Type 1 Study Group. Incident dysglycemia and the progression to type 1 diabetes among participants in the Diabetes Prevention Trial-Type 1. Diabetes Care 2009;32:1603-1607
2. Diabetes Prevention Trial-Type 1 Diabetes Study Group. Effects of insulin in relatives of patients with type 1 diabetes mellitus. N Engl J Med 2002;346:1685-1691
3. Diabetes Prevention Trial-Type 1 Diabetes Study Group. Effects of oral insulin in relatives of patients with type 1 diabetes. Diabetes Care 2005;28:1068-1076
4. Sosenko JM, Palmer JP, Rafkin-Mervis L, Krischer JP, Cuthbertson D, Greenbaum CJ, Eisenbarth G, Skyler JS. Trends of earlier and later responses of C-peptide to oral glucose challenges with progression to type 1 diabetes in Diabetes Prevention Trial-Type 1 participants. Diabetes Care 2010;33:620-625
5. Sosenko J, Palmer JP, Greenbaum CJ, Mahon J, Cowie C, Krischer JP, Chase HP, White NH, Buckingham B, Herold KC, Cuthbertson D, Skyler JS, the Diabetes Prevention Trial-Type 1 Study Group. Patterns of metabolic progression to type 1 diabetes in the diabetes prevention trial-type 1. Diabetes Care 2006;29:643-649
6. Yalow RS, Glick SM, Roth J, Berson SA. Plasma insulin and growth hormone levels in obesity and diabetes. Ann N Y Acad Sci 1965;131:357-373
7. Bagdade JD, Bierman EL, Porte Jr D. The significance of basal insulin levels in the evaluation of the insulin response to glucose in diabetic and nondiabetic subjects. J Clin Invest 1967;41:1549-1557
8. Greenbaum CJ. Insulin resistance in type 1 diabetes. Diabetes Metab Res Rev 2002;18:192-200
9. Xu P, Cuthbertson D, Greenbaum C, Palmer JP, Krischer JP, the Diabetes Prevention Trial-Type 1 Study Group. Role of insulin resistance in predicting progression to type 1 diabetes. Diabetes Care 2007;30:2314-2320
10. Fourlanos S, Narendran P, Byrnes GB, Colman PG, Harrison LC. Insulin resistance is a risk factor for progression to type 1 diabetes. Diabetologia 2004;47:1661-1667
11. Mrena S, Virtanen SM, Laippala P, Kulmala P, Hannila ML, Åkerblom HK, Knip M, the Childhood Diabetes in Finland Study Group. Models for predicting type 1 diabetes in siblings of affected children. Diabetes Care 2006;29:662-667
12. Bingley PJ, Mahon JL, Gale EAM for the European Nicotinamide Diabetes Intervention Trial (ENDIT) Group. Insulin resistance and progression to type 1 diabetes in the European Nicotinamide Diabetes Intervention Trial (ENDIT). Diabetes Care 2008;31:146-150
13. Yki-Yarvinen H, Koivisto VA. Natural course of insulin resistance in type 1 diabetes. N Engl J Med 1986;315:224-230
14. Martin S, Pawlowski B, Greulich B, Ziegler AG, Mandrup-Poulsen T, Mahon J. Natural course of remission in IDDM during 1st year after diagnosis. Diabetes Care 1992;15:66-74
15. Robertson RP, Harmon J, Tran PO, Tanaka Y, Takahashi H. Glucose toxicity in β-cells: type 2 diabetes, good radicals gone bad, and the glutathione connection. Diabetes 2003;52:581-587